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Postherpetic neuralgia (PHN) is a 
chronically painful condition that is a 
complication of shingles (acute herpes 
zoster), a recurrence of the varicella-
zoster virus, which initially causes 
chickenpox. Although shingles usually 
resolves within a month, some people 
continue to feel the pain of PHN long 
after the rash and blisters heal, because of 
nerve damage (neuropathic pain) caused 
by the shingles. Not everyone who has 
had shingles develops PHN, although it 
is a common complication of shingles in 
older adults. 
Despite advances in antiviral therapy 
during acute herpes zoster and the 
more recent introduction of vaccination 
against varicella zoster, PHN continues 
to be a signiﬁ  cant clinical problem, with 
10–20% of patients developing persistent 
neuropathic pain after acute herpes zoster 
reactivation. The nature of PHN pain is 
variable, which implies that a variety of 
mechanisms might be operating. This 
variability has led to the hypothesis that 
treatment plans could be optimised for 
individual patients on the basis of the 
individual pattern of their symptoms or 
the underlying mechanism of the pain.
However, the current evidence base for 
therapies in PHN is based on clinical trials 
of analgesics, which have examined PHN 
as a single disease entity. Furthermore, 
there is little evidence for the efﬁ  cacy of 
drugs for speciﬁ  c sets of symptoms and 
no simple way to determine which pain 
mechanisms might be operating in an 
individual patient.
In this month’s PLoS Medicine,
Andrew Rice and colleagues reassessed 
the evidence base by doing a 
systematic review and meta-analysis of 
analgesic therapy for PHN, which has 
fundamentally changed in the wake of 
several major new trials. The authors 
searched the literature for trials of PHN 
and retrieved 62 articles, of which 35 
were kept for ﬁ  nal analysis. 
Their analysis conﬁ  rmed several 
previous research ﬁ  ndings, although they 
cautioned that the meta-analytic study 
design of collecting data from a range of 
trials had several inherent pitfalls, and it 
is difﬁ  cult to directly compare treatments 
across different trials.
However, they found evidence for 
analgesic efﬁ  cacy in established PHN for 
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It doesn’t take a trained physician 
to know that a disease needs to be 
diagnosed to be treated. And it doesn’t 
take an economist to know that a disease 
cannot be diagnosed if the required 
tools are unaffordable or impractical. The 
absence of early diagnosis and treatment 
is particularly problematic for infectious 
disease, where the lack of early treatment 
or isolation can result in an epidemic. 
Given the technological requirements, 
diagnosis and monitoring of HIV infection 
is problematic in resource-poor areas. 
The advent of rapid tests for diagnosing 
HIV infection represents one part of 
the solution. Less clear is how patients 
diagnosed with HIV infection will be 
monitored, given the importance of 
CD4 cell counts. A decrease in CD4+ T 
lymphocytes—a critical immune cell 
infected by HIV—is one of the hallmarks 
of HIV disease, and CD4+ cell number 
is a key factor in determining disease 
progression and monitoring treatment. 
The methods for determining CD4+
cell numbers are technically complex, 
expensive, and not easily transportable. 
These factors severely limit the ability to 
monitor HIV disease in locations where 
resources, training, and mobility are 
limited.
Towards a Cheap and Easy Way to Monitor HIV/AIDS
DOI: 10.1371/journal.pmed.0020242
orally administered therapies, such as 
tricyclic antidepressants, some opioids, 
gabapentin, tramadol, and pregabalin. 
Some topically administered therapies, 
such as lidocaine and capsaicin, were 
associated with analgesic efﬁ  cacy in 
selected patients. However, it appeared 
that therapies such as oral administration 
of certain NMDA receptor antagonists, 
codeine, ibuprofen, lorazepam, 5HT1 
receptor agonists, and acyclovir were not 
efﬁ  cacious in PHN.
Altogether, the authors conclude that 
the evidence base supports the ﬁ  rst-line 
use of a tricyclic antidepressant for orally 
administered treatment of PHN, reserving 
the gabapentinoids for second-line use. 
Topical treatments, such as lidocaine 
or capsaicin, should be considered as 
ﬁ  rst-line treatment if a patient falls into 
the “sensitised nociceptor” as opposed 
to “deafferentation” sub-group of PHN 
patients.
The role of intrathecal steroid is still not 
clear: one trial indicated that intrathecal 
steroids were associated with beneﬁ  ts 
in patients with PHN, but this therapy 
might be hazardous, and the authors and 
other researchers have concluded that 
further high-quality trials of this therapy 
are needed. The authors found little 
evidence regarding possible synergistic 
effects of the various treatments to 
support or refute the concomitant use of 
combinations of drugs.
They stressed that any treatment 
plan must recognise the importance of 
the biopsychosocial model of chronic 
pain and that any pharmacologically 
based management of PHN should 
be combined with advice on and 
management of psychological and social 
aspects.
Finally, as there is no single 
pathophysiology that underlies PHN, they 
propose that future studies should use 
quantitative sensory evaluation to clearly 
categorise subsets of participants for 
better interpretation of treatment effects.
Hempenstall K, Nurmikko TJ, Johnson 
RW, A’Hern RP, Rice ASC (2005) Analgesic 
therapy in postherpetic neuralgia: A 
quantitative systematic review. DOI: 
10.1371/journal.pmed.0020164
DOI: 10.1371/journal.pmed.0020242.g001
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When the SARS epidemic showed the ﬁ  rst signs of waning, 
the World Health Organization proclaimed that the turnaround 
was a testament to the efﬁ  cient response of health systems 
worldwide and justiﬁ  ed its decisive action in issuing a global 
alert.
That swift response was partly due to infectious disease 
experts being able to use models of disease spread, even 
though SARS was a newly emerging disease, to help plan their 
next move. In fact, epidemiologists have used mathematical 
models to predict and understand the dynamics of infectious 
diseases for more than 200 years. The emergence of diseases 
such as Ebola, SARS, and West Nile virus, and multi-drug-resistant 
malaria—as well as the potential for diseases to be introduced 
by bioterrorism—has attached even greater importance to this 
management tool. 
Models are used to provide information on such infections 
and predict the effect of alternative courses of action. In this 
month’s PLoS Medicine, Helen Wearing and colleagues suggest, 
however, that many off-the-shelf models are inappropriate for 
making quantitative predictions because substantial biases 
have been introduced by two important, yet largely ignored, 
assumptions. The authors warn that if such biases are not 
corrected, health authorities risk making overly optimistic 
health policy decisions.
They begin with the “SEIR” class of models, in which the 
host population is classiﬁ  ed according to infectious status, i.e., 
individuals are susceptible, exposed, infectious, or recovered. This 
model assumes that the rate of leaving the exposed or infectious 
class is constant, irrespective of the time already spent in that 
class. Although mathematically convenient, this assumption 
gives rise to exponentially distributed latent (incubation) and 
infectious periods, which is epidemiologically unrealistic for most 
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Estimates of variation in the basic reproductive ratio
Lymphocytes are characterized 
by cell surface markers; thus, CD4+
lymphocytes express the CD4 marker 
on their surface. Antibody probes that 
speciﬁ  cally recognize this and other 
cell surface markers (such as CD8, 
which distinguishes that lymphocyte 
population from CD4+ lymphocytes, 
and CD3, which is a marker for all T 
lymphocytes) are used to count and 
differentiate various cell populations. By 
labeling cells with ﬂ  uorescently tagged 
antibodies that recognize one or more 
cell surface molecules, the relative and 
absolute numbers of speciﬁ  c cells can be 
determined by a technique called ﬂ  ow 
cytometry. The labeled cells are passed 
through the ﬂ  ow cytometer, where the 
ﬂ  uorescent probes are activated by 
lasers in a manner that can be read by 
speciﬁ  c detectors. The CD4+ cell number 
is directly correlated with the resultant 
ﬂ  uorescent intensity and other light 
scatter properties. The problem is that 
ﬂ  ow cytometry requires costly reagents 
and substantial technical expertise—
factors that limit its use in less developed 
areas.
Taking advantage of advances in 
microﬂ  uidics, digital imaging, and 
cell analysis, William Rodriguez and 
colleagues now report on a way to count 
CD4+ cells in a relatively quick, easy, and 
affordable manner. Small volumes of 
blood (an amount that could be obtained 
by a ﬁ  nger prick as opposed to drawing 
blood from a vein) are labeled as in 
ﬂ  ow cytometry, but with far less of the 
expensive reagents. Microﬁ  ltration allows 
the labeled CD4+ cells to be captured 
and separated from red blood cells, 
another simpliﬁ  cation relative to ﬂ  ow 
cytometry. Digital images of the labeled 
cells, obtained by digital ﬂ  uorescence 
microscopy, are then analyzed by newly 
developed software that can distinguish 
the CD4, CD8, and CD3 labels, thus 
allowing determination of absolute CD4+
counts, CD4+ percentages, and CD4+:CD8+
lymphocyte ratios. 
Rodriguez et al. found that this new 
method was less accurate than ﬂ  ow 
cytometry for determining absolute 
CD4+ lymphocyte counts above 500 
cells/mm3 (levels that are typically not 
relevant for monitoring HIV-infected 
individuals). But the method was as 
accurate as ﬂ  ow cytometry at clinically 
relevant levels of CD4+ cells for HIV-
infected adult individuals. Although only 
a small number of pediatric patients 
were examined (and thus statistical 
signiﬁ  cance could not be ascertained), 
the method appears to be also effective 
in determining CD4+ lymphocyte 
percentages in children. 
The detection system used in the 
present report is a tabletop instrument 
that serves as a prototype for a fully 
portable handheld model, which is now 
under development. After some modest 
training, such a tool should allow a variety 
of health-care workers in remote areas to 
accurately analyze the CD4+ status of HIV-
infected patients (the basis for treatment 
decisions) locally. In an accompanying 
Perspective discussing this new tool 
(DOI: 10.1371/journal.pmed.0020214), 
Zvi Bentwich argues that before it is 
ready for widespread use, several issues 
still need to be resolved, such as its ﬁ  nal 
cost and its applicability to pediatric 
patients. “Despite these reservations,” he 
says, “the authors of this study should be 
commended for addressing an extremely 
important issue and developing this 
novel approach for counting CD4 in 
patients with HIV.”
Rodriguez WR, Christodoulides N, Floriano 
PN, Graham S, Mohanty S, et al. (2005) A 
microchip CD4 counting method for HIV 
monitoring in resource-poor settings. DOI: 
10.1371/journal.pmed.0020182
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infections, say the authors, who suggest instead that it would 
more sensible to specify the probability of leaving a class as a 
function of the time spent within the class. Hence, initially, the 
chance of leaving the class is small but then increases as the 
mean infectious/incubation period is reached. This assumption 
would give a more realistic distribution of incubation and 
infectious periods.
The authors also note another issue that has received 
surprisingly little attention in infectious disease models, namely, 
the inﬂ  uence of incubation and infectious period distributions 
on the invasion dynamics of an infection into a largely 
susceptible population—despite its obvious application to 
emerging infections and possible “deliberate exposure.”
The impact of these differences on models could translate 
into potentially important public health concerns, say the 
authors. They tested their theory by using analytical methods 
to show that, ﬁ  rst, ignoring the incubation period or, second, 
assuming exponentially distributed incubation and infectious 
periods (when including the incubation period) always resulted 
in underestimating the basic reproductive ratio of an infection 
from outbreak data. They then illustrated these points by ﬁ  tting 
epidemic models to data from an inﬂ  uenza outbreak. Their 
results suggested that within a strict management setting, 
epidemiological details could make a crucial difference. 
Although previous studies have shown the importance of 
using realistic distributions of incubation and infectious periods 
in endemic disease models, few studies have considered the 
effects associated with making predictions for an emerging 
disease. Discrepancies between estimates of reproductive ratio 
from exponentially distributed and gamma-distributed ﬁ  ts 
conﬁ  rm the need to have precise distributions of incubation and 
infectious periods. Although such data are available from post 
hoc analyses of epidemics, they are lacking for novel emerging 
infections. The key point is that uncertainty about these 
distributions should be incorporated into models when making 
quantitative predictions.
The take home message is that when developing models 
for public health use, policy makers need to pay attention 
to the intrinsic assumptions within classical models. The 
authors note that while some practitioners are using their 
approach, most applied epidemiological studies still use 
models that incorporate exponentially distributed incubation 
and infectious periods; the authors hope their work will 
point to the next steps in delivering quantitatively accurate 
epidemiological models.
Wearing HJ, Rohani P, Keeling MJ (2005) Appropriate models for 
the management of infectious diseases. DOI: 10.1371/journal.
pmed.0020174
There are at least 300 million 
acute cases of malaria each year 
globally, resulting in more than 
a million deaths. Ninety percent 
of deaths due to malaria occur in 
Africa, south of the Sahara, mostly 
in young children. The number 
of deaths is increasing, and one 
key factor linked to this has been 
widespread drug resistance 
of Plasmodium falciparum to 
conventional antimalarials, such 
as sulfadoxine-pyrimethamine 
(SP); such resistance is 
widespread in southeast Asia, 
South America, and Africa. The 
inappropriate use of antimalarials 
during the past century has 
contributed to this increase 
in resistance. For example, there has 
been overreliance on quinolines (such 
as chloroquine) and antifolates (such 
as pyrimethamine) resulting in cross-
resistance among these drug classes. 
However, in the past decade, a new 
group of antimalarials—the artemisinin 
compounds, such as artesunate, 
artemether, and dihydroartemisinin—
have been deployed on an increasingly 
large scale. 
These compounds produce a very 
rapid therapeutic response, are active 
against parasites resistant to multiple 
drugs, are well tolerated, and reduce 
gametocyte carriage. To date, no parasite 
resistance to these compounds has 
been detected.
If used alone, the artemisinins will 
cure falciparum malaria in seven days, 
but studies in southeast Asia have 
shown that combinations of artemisinin 
compounds with certain synthetic drugs 
produce high cure rates after just three 
days of treatment. There is also some 
evidence that combinations of therapies 
could greatly retard development of 
resistance to the partner drug. Although 
combinations including artemisinins 
have been widely advocated, they are 
expensive and relatively untested 
in highly endemic areas.
In this month’s PLoS Medicine,
Adoke Yeka and colleagues 
compared artemisinin-
based compounds and other 
combination therapies in 
four districts with varying 
transmission intensity in Uganda 
in 2,160 patients aged six months 
or greater with uncomplicated 
falciparum malaria. The team 
tested the combination of 
chloroquine and SP, currently the 
ﬁ  rst-line therapy in Uganda, the 
combination of amodiaquine and 
SP, a cheap regimen proven to be 
efﬁ  cacious in previous trials, and 
the combination of amodiaquine 
and artesunate. 
During the 28-day study they collected 
data on the efﬁ  cacy of the different 
regimens and examined the effect on 
recrudescence and new infections after 
therapy. Combined amodiaquine and 
artesunate was the most efﬁ  cacious 
regimen for preventing recrudescence, 
but this beneﬁ  t was outweighed by 
an increased risk of new infection. This 
result was probably due to artesunate 
being rapidly eliminated, leaving 
only amodiaquine to provide post-
treatment prophylaxis. Considering all 
recurrent infections, the combination 
Which Combination Therapy for Uncomplicated Malaria in Africa?
DOI: 10.1371/journal.pmed.0020236
DOI: 10.1371/journal.pmed.0020236.g001
A trial site in Uganda 
July 2005  |  Volume 2  |  Issue 7  |  e239  |  e236PLoS Medicine  |  www.plosmedicine.org 0574
of amodiaquine and SP was at least as 
efﬁ  cacious as the other combinations 
at all sites and superior at the highest 
transmission sites.
In all, 72% of all recurrent infections 
were due to new infections, and with 
the two most efﬁ  cacious regimens 
(amodiaquine and SP, and amodiaquine 
and artesunate) this proportion was 
80%. The identiﬁ  cation of new infections 
stressed the need for other malaria 
control measures, such as bed nets, said 
the authors.
They also suggested that antimalarials 
should be judged not just on their 
impact on recrudescence but also 
on their impact on the risk of new 
infections after therapy. Previous 
studies have suggested that patients 
who suffer recrudescence have a 
higher risk of complicated malaria 
and death. Artemisinins are highly 
attractive antimalarials, but when used 
as monotherapy, they have a high risk 
of recrudescence and hence must be 
combined with other antimalarials to 
achieve maximum efﬁ  cacy. But whether 
the partner drug should be long or short 
acting remains unclear, said the authors.
Altogether, artemisinin combinations 
offer great hope for Africa, the authors 
say, although the ideal combination 
regimen remains uncertain and cost 
is a problem. To compare the efﬁ  cacy 
of the different therapies, bigger and 
longer controlled trials are needed 
in conditions of varied transmission 
intensity. Nevertheless, based on the 
results of this study and others, Uganda 
has chosen a combination of artemether 
and lumefantrine as its ﬁ  rst-line therapy 
against malaria.
Yeka A, Banek K, Bakyaita N, Staedke SG, 
Kamya MR, et al. (2005) Artemisinin versus 
nonartemisinin combination therapy for 
uncomplicated malaria: Randomized clinical 
trials from four sites in Uganda. DOI: 
10.1371/journal.pmed.0020190
Hepatitis B is a serious global public health problem but is 
preventable with safe and effective vaccines that have been 
available since 1982. Despite these vaccines, about 2 billion 
people have been infected with hepatitis B virus (HBV), 
and more than 350 million have lifelong infections. These 
chronically infected people are at high risk of death from 
cirrhosis of the liver and liver cancer, which both kill about 1 
million people each year.
Suppression of viral replication in chronic carriers of HBV 
is an effective approach to controlling disease progression. 
Current antiviral therapies include lamivudine and alpha-
interferon, but long-term resolution of the disease is 
disappointing because of low seroconversion rates and the 
development of drug-resistant viral mutants.
In this month’s PLoS Medicine, Lisa F. P. Ng and colleagues 
describe the identiﬁ  cation of a host factor that has a 
signiﬁ  cant effect on viral replication efﬁ  ciency. The team 
began by examining the serum viral load of a group of 
carriers of hepatitis B in relation to the HBV genome carried. 
They found a signiﬁ  cant association between high serum 
viral load and a natural sequence variant within the HBV 
enhancer II regulatory region at position 1752. Upon testing 
all four possible 1752 variants, the 1752A variant had the 
highest transcriptional activity.
Further investigation of this enhanced transcriptional 
activity revealed evidence of possible interaction with host 
DNA binding proteins. The team found that a protein present 
in the human host—hnRNPK—could be isolated by direct 
binding to a viral fragment derived from the HBV variant of 
these infected patients.
hnRNPK has previously been shown to be involved in 
several cellular functions—for example, as a regulator of 
signal transduction and of gene expression. On further 
examination of the role of hnRNPK in HBV replication, they 
established that hnRNPK is capable of acting on the full 
length of HBV, rather than just a partial fragment. They 
compared four full-length replicative HBV clones, identical 
except for a single base change at position 1752, that were 
transfected with two different hnRNPK expression constructs 
and showed that 1752A was more efﬁ  cient at promoting 
replication than the other three variants.
To further show the role of hnRNPK in HBV replication, 
the team tested the effect of over-expression and down-
regulation of the cellular protein. Using siRNA, designed to 
reduce endogenous hnRNPK, they showed suppression of 
both hnRNPK mRNA and HBV viral load, whereas a control 
siRNA had no effect on HBV viral load.
Despite these ﬁ  ndings, the mechanism behind hnRNPK on 
HBV replication needs further exploration, the authors say, 
concluding that viral replication efﬁ  ciency was determined 
by a combination of viral sequence and interaction with 
speciﬁ  c host proteins. However, they suggest that these 
results indicate that although drug development of antivirals 
is an established research avenue, targeting the host is an 
untapped opportunity.
They describe parallels with anti-EGFR antibody treatment 
of breast cancer cells, which produced a decrease in cell 
replication rate and corresponding reduction in hnRNPK 
expression levels; this result suggested that hnRNPK 
levels could be modulated by anti-EGFR treatment, thus 
highlighting new treatment options for altering the HBV viral 
load in chronic carriers.
The authors conclude that the future of long-term viral 
clearance will require combination therapy of targeting the 
virus directly, blocking host support proteins, and using 
immuno-modulating agents.
Ng LFP, Chan M, Chan SH, Cheng PCP, Leung EHC, et al. (2005) 
Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential 
target to suppress hepatitis B virus replication. DOI: 10.1371/
journal.pmed.0020163
Targeting of a Host Protein to Suppress Hepatitis B Virus Replication
DOI: 10.1371/journal.pmed.0020237
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Twins’ research is a favorite tool of the human geneticist, but it 
has a controversial history. Nazi doctor Josef Mengele, infamous 
for his work at Auschwitz, was fascinated by twins. He sought 
them out at the extermination camp and used them in violent 
experiments. Later, British psychologist Cyril Burt worked on the 
heredity of intelligence, producing ﬁ  ndings that some suspected 
were “too good”—and which later were shown to be based on 
fraudulent data involving invented twins.
In this month’s PLoS Medicine, Nancy Krieger and colleagues 
examine the health of female twins from a very different 
perspective. To understand the impact of lifetime socioeconomic 
position on health, they studied twins who were raised together 
but who had different socioeconomic position after adolescence. 
Many studies have compared the health of twins raised separately 
since birth or early childhood, but few have investigated the 
adult health of twins raised together but who had different post-
adolescent socioeconomic position. Such a study could clarify 
the impact of adult experiences on adult health in a population 
matched on early life experiences, the authors say.
Krieger’s team employed data from a cohort of 434 twins who 
lived in the San Francisco Bay area in 1978–1979; the average age 
at recruitment was 41 years old. The cohort was given a health 
and sociodemographic questionnaire. Data on anthropometric 
and biological characteristics were obtained by physical 
examination and laboratory analyses; the process was repeated 
at a second examination around 1989–1990. At the second phase 
of the study, 72 women (8.3%) did not return, of whom 36 had 
died, which left 352 twin pairs (58% monozygotic, 42% dizygotic), 
representing 81.1% of the original cohort.
The sociodemographic and health characteristics of the full 
cohort (352 pairs) and the cohort analyzed (those pairs where it 
was known both that they had lived together until at least age 
14 and their joint socioeconomic was available—i.e., 308 pairs) 
were quite similar: 40% grew up in working-class households 
and 80% in households where the father had fewer than four 
years of college education.
At the second examination, 32% of the twin pairs in the 
analytic cohort had a difference in their adult household 
occupational class, and 20% had different levels of college 
education. The team found that health outcomes among 
monozygotic adult female twins who lived together through 
childhood varied by their subsequent socioeconomic position. 
Twins with differing occupational class differed in health 
status compared with twins with similar occupational class. 
The working-class twin had signiﬁ  cantly higher systolic blood 
pressure, diastolic blood pressure, and LDL cholesterol than 
her professional, non-working-class twin. Twins discordant 
on educational level, however, had similar health status, likely 
reﬂ  ecting the fact that current occupational class is a better 
measure for investigating the impact of lifetime socioeconomic 
position than is education (which is completed usually in early 
adulthood). Dizgyotic twins with differing adult socioeconomic 
position, either occupational class or educational level, did not 
notably differ in their adult health status.
These novel ﬁ  ndings lend support to the hypothesis that 
health is shaped not only by early life experiences but also by 
cumulative experiences across the lifecourse, the authors say. 
As with many twin studies, the numbers of individuals studied 
is relatively limited. The lack of some biological and personal 
data such as detailed occupational class position over time, 
lack of data on income, poverty, wealth, debt, gestational age, 
birthweight, and birth order also limits the conclusions that can 
be drawn. These limitations are countered, however, by the tight 
matching of the twins on early life and childhood exposures, 
as well as by the matching for genetic endowment among 
the monozygotic twins. Together, the ﬁ  ndings have important 
implications for health policy, since they suggest that adult 
socioeconomic position does have an impact on adult health 
above and beyond early life exposures, and they also add to our 
understanding of how societal conditions shape population 
patterns of health, disease, and well-being.
Krieger N, Chen JT, Coull BA, Selby JV (2005) Lifetime 
socioeconomic position and twins’ health: An analysis of 308 pairs of 
United States women twins. DOI: 10.1371/journal.pmed.0020162
Twins’ Health and Adult Socioeconomic Status
DOI: 10.1371/journal.pmed.0020235
DOI: 10.1371/journal.pmed.0020235.g001
Twins in the womb (from the ﬁ  rst US textbook on midwifery, An
Abridgement of the Practice of Midwifery, by W. Smellie, 1786)
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